We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00610844
First Posted: February 8, 2008
Last Update Posted: February 20, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
University Hospital Tuebingen
  Purpose
The purpose of the study is to evaluate the effectiveness of radiofrequency ablation by pathological correlation and to characterize the tissue response after treatment of primary and secondary pulmonary tumors.

Condition Intervention Phase
Lung Cancer Lung Metastasis Procedure: pulmonary radiofrequency ablation Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Effectiveness of Preoperative Percutaneous Radiofrequency Ablation of Primary and Secondary Lung Tumors

Resource links provided by NLM:


Further study details as provided by University Hospital Tuebingen:

Primary Outcome Measures:
  • rate of incomplete treated tumors [ Time Frame: 3 days ]

Secondary Outcome Measures:
  • pathologic tissue changes, rate of major and minor complications [ Time Frame: 6 months ]

Enrollment: 9
Study Start Date: April 2004
Primary Completion Date: May 2006 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
pulmonary radiofrequency ablation
Procedure: pulmonary radiofrequency ablation
CT-guided pulmonary radiofrequency ablation

Detailed Description:
Thermal ablation therapy is an increasingly performed technique in the local tumor treatment. Among these techniques, image-guided radiofrequency (RF) ablation attained widespread consideration in the therapy of liver tumors and osteoid osteoma. Promising results of hepatic RF ablation raised expectations to utilize the advantages of image-guided ablation therapy for the treatment of pulmonary malignancies. The purpose of the study is to evaluate the effectiveness of radiofrequency ablation by pathological correlation and to characterize the tissue response after treatment of primary and secondary pulmonary tumors. Computed tomography-guided RF ablation is performed in local or general anesthesia, followed by surgical resection three days later. An analysis of complete RF ablation and a characterization of tissue response is performed by hematoxylin and eosin staining, immunostaining, and electron microscopy. Adverse effects and complications are recorded.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Signed informed consent for radiofrequency ablation and surgery
  • Maximum of 3 lung tumors
  • Maximum tumor size 5 cm
  • Must be able to receive standard surgery

Exclusion Criteria:

  • Pathological coagulation tests
  • Pregnant or breast feeding
  • Maximum tumor size more than 5 cm
  • Bilateral secondary lung cancer with more than 3 tumors
  • Inoperable patient
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00610844


Locations
Germany
Department of Diagnostic Radiology
Tübingen, BW, Germany, 72076
Sponsors and Collaborators
University Hospital Tuebingen
Investigators
Principal Investigator: Philippe L Pereira, MD Department of Diagnostic Radiology, University of Tübingen
Principal Investigator: Hermann Aebert, MD Department of thoracic surgery, University of Tübingen
  More Information

Responsible Party: Philippe L. Pereira, MD, Department of Diagnostic Radilogy
ClinicalTrials.gov Identifier: NCT00610844     History of Changes
Other Study ID Numbers: LungRFA_V1
First Submitted: January 28, 2008
First Posted: February 8, 2008
Last Update Posted: February 20, 2008
Last Verified: November 2007

Keywords provided by University Hospital Tuebingen:
lung cancer
lung metastasis
radiofrequency ablation

Additional relevant MeSH terms:
Neoplasm Metastasis
Neoplastic Processes
Neoplasms
Pathologic Processes